A5033464248- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Venous Thromboembolism Diagnosis and Management
- MRI in cancer diagnosis
- Liver Disease and Transplantation
- Liver Disease Diagnosis and Treatment
- Renal cell carcinoma treatment
- Central Venous Catheters and Hemodialysis
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Organ Transplantation Techniques and Outcomes
- Colorectal Cancer Treatments and Studies
- Hepatitis B Virus Studies
- Medical Imaging and Pathology Studies
- Atrial Fibrillation Management and Outcomes
- Advanced Radiotherapy Techniques
- Gallbladder and Bile Duct Disorders
- Multiple and Secondary Primary Cancers
- Lung Cancer Research Studies
- Radiation Dose and Imaging
- Nanoparticle-Based Drug Delivery
- Lung Cancer Diagnosis and Treatment
Northwestern University
2016-2025
Northwestern Memorial Hospital
2016-2025
Duke Medical Center
2024
Michigan Medicine
2024
Cornell University
2024
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
2013-2023
Society of Interventional Radiology
2008-2023
Indo-American Center
2010-2023
Siemens Healthcare (United States)
2023
American College
2023
Chemoembolization is one of several standards care treatment for hepatocellular carcinoma (HCC). Radioembolization with Yttrium-90 microspheres a novel, transarterial approach to radiation therapy. We performed comparative effectiveness analysis these therapies in patients HCC.We collected data from 463 who were treated locoregional (chemoembolization or radioembolization) over 9-year period. excluded not appropriate comparison and analyzed 245 (122 received chemoembolization 123...
This study was undertaken to present data from a phase 2 in which patients with unresectable hepatocellular carcinoma (HCC) and without portal vein thrombosis underwent radioembolization Yttrium (90Y) microspheres. Patients treated were stratified by Okuda, Child-Pugh, baseline bilirubin, tumor burden, Eastern Cooperative Oncology Group (ECOG), presence of cirrhosis (PVT) (none, branch, main). Clinical biochemical obtained at 4-week intervals following treatment for up 6 months. Tumor...
Conventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded yttrium-90 (Y90) inside the blood vessels supply tumor. We performed randomized, phase 2 study compare effects cTACE and Y90 radioembolization in HCC.
Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unresectable HCC. The aim LEGACY (Local radioEmbolization using Glass Microspheres for Assessment Tumor Control with Y-90) study was to evaluate objective response rate (ORR) and duration (DoR) patients solitary HCC treated glass microspheres.LEGACY is a multicenter, single-arm, retrospective conducted at three sites that included all eligible, consecutive radioembolization between 2014...
To present the clinical data of 35 patients with T3 unresectable hepatocellular carcinoma (HCC) that were treated (90)Y specific intent downstaging to resection, radiofrequency ablation (RFA) candidate, United Network for Organ Sharing (UNOS) stage T2 or liver transplantation.One hundred fifty HCC microspheres. Of these, UNOS at time treatment. Patients followed toxicities, alterations in model end-stage-liver disease (MELD) score, tumor response, RFA, transplantation, and survival.Nineteen...
Resection and radiofrequency ablation (RFA) are treatment options for hepatocellular carcinoma (HCC) <3 cm; there is interest in expanding the role of to 3-5 cm. RFA considered high-risk when lesion close proximity critical structures. Combining microcatheter technology localized emission properties Y90, highly selective radioembolization a possible alternative such cases. We assessed efficacy (response, radiology-pathology correlation, survival) radiation segmentectomy solitary HCC not...
Yttrium‐90 transarterial radioembolization (TARE) is a locoregional therapy (LRT) for hepatocellular carcinoma (HCC). In this study, we present overall survival (OS) outcomes in 1,000‐patient cohort acquired over 15‐year period. Between December 1, 2003 and March 31, 2017, 1,000 patients with HCC were treated TARE as part of prospective study. A comprehensive review toxicity was performed. Outcomes stratified by baseline Child‐Pugh (CP) class, United Network Organ Sharing (UNOS), Barcelona...
Purpose To report long-term outcomes of radiation segmentectomy (RS) for early hepatocellular carcinoma (HCC). The authors hypothesized that are comparable to curative treatments patients with solitary HCC less than or equal 5 cm and preserved liver function. Materials Methods This retrospective study included 70 (median age, 71 years; range, 22–96 years) not amenable percutaneous ablation who underwent RS (dose >190 Gy) between 2003 2016. Patients subsequent transplantation were excluded...
We present the correlation between radiologic and pathologic findings in HCC patients who underwent radioembolization with yttrium-90 ((90)Y) microspheres prior to resection or transplantation. Thirty-five a total of 38 lesions liver explantation after (90)Y were studied. Imaging surrogates following treatment evaluated; explants examined for assessment necrosis by pathology. The histologic treated was analyzed. Twenty-three (61%) target showed complete necrosis. All demonstrated some degree...
In Brief Purpose: Minimally invasive therapies such as transarterial chemoembolization and radiofrequency ablation are used for hepatic metastatic neuroendocrine tumor (NET) therapy. Results from another minimally therapy, radioembolization, remain unknown. The purpose of this multicenter open label phase II study was to assess the efficacy safety yttrium-90 (90Y) radioembolization treating NET using a primary outcome response secondary outcomes serologic toxicities survival....
Purpose: To prospectively evaluate the safety, efficacy, and survival of patients with chemorefractory liver metastases who have been treated yttrium 90 (90Y) glass microspheres. Materials Methods: Institutional review boards from two institutions approved HIPAA-compliant study; all provided informed consent. One hundred thirty-seven underwent 225 administrations 90Y microspheres by using intraarterial infusion. Primary sites (origins) included colon, breast, neuroendocrine, pancreas, lung,...